Dharmisha Chauhan
@dharmisha.bsky.social
Consultant Pharmacist - Genomic Medicine at North Thames Genomic Medicine Service Alliance and Specialist Oncology Pharmacist - Lung Cancer at Royal Marsden Hospital Pharmacogenomics; Pharmacy; Oncology; Books & Coffee Views are my own 🤓 ☕️📚🍂
"Lung cancer is a rapidly fatal disease. Speedy access to test results and effective treatments is vital," says @profrobertrintoul.bsky.social, UKLCC’s Clinical Lead. Read our report on how we can streamline the #GenomicTesting pathway and improve outcomes for patients ow.ly/BX3X50V9wCB
🔥BREAKING🆙 ✅3️⃣cycles of Pre-ope Nivo + Chemo showed a statistically significant and clinically meaningful overall survival benefit 🎯Second OS positive following KEYNOTE 671 (pembro pre4️⃣ + post1️⃣3️⃣) in resectable NSCLC 🎙️ @bms-news.bsky.social #LCSM @oncoalert.bsky.social news.bms.com/news/corpora...
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survi...
Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo ® (nivolumab) in combination with platinum-do...
news.bms.com
Guidelines for managing #tarlatamab - associated toxicities in #SCLC #lcam #lcsm acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer
Tarlatamab received accelerated approval from the US Food and Drug Administration for the treatment of patients with previously treated small cell lung cancer. This review summarizes the safety profi....
acsjournals.onlinelibrary.wiley.com
In a book classed as essential knowledge, there is a brilliant chapter on pharmacogenomics authored by @dharmisha.bsky.social & editing led by Raliat on this one.
